The US FDA’s proposed rule on laboratory-developed tests: Impacts on clinical laboratory testing
Contents
Appearance
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H19FN4 |
Molar mass | 310.376 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
CP-226,269 is a drug which acts as a dopamine agonist selective for the D4 subtype, which is used for researching the role of D4 receptors in the brain.[1][2]
References
- ^ Sharma A, Kramer ML, Wick PF, Liu D, Chari S, Shim S, Tan W, Ouellette D, Nagata M, DuRand CJ, Kotb M, Deth RC (May 1999). "D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia". Molecular Psychiatry. 4 (3): 235–46. doi:10.1038/sj.mp.4000522. PMID 10395213.
- ^ Basso AM, Gallagher KB, Bratcher NA, Brioni JD, Moreland RB, Hsieh GC, Drescher K, Fox GB, Decker MW, Rueter LE (July 2005). "Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test". Neuropsychopharmacology. 30 (7): 1257–68. doi:10.1038/sj.npp.1300677. PMID 15688083.